Page 1 | Search Results | Cancer Immunology Research | American Association for Cancer Research

1-8 of 8

Sort by

Sort Order Select

Journal Articles

IDO Vaccine Ablates Immune-Suppressive Myeloid Populations and Enhances Antitumor Effects Independent of Tumor Cell IDO Status

Rahul Nandre, Vivek Verma, Pankaj Gaur, Veerupaxagouda Patil, Xingdong Yang, Zainab Ramlaoui, Nour Shobaki, Mads Hald Andersen, Ayako Wakatsuki Pedersen, Mai-Britt Zocca, Mikayel Mkrtichyan, Seema Gupta, Samir N. Khleif

Cancer Immunol Res (2022) 10 (5): 571–580.

https://doi.org/10.1158/2326-6066.CIR-21-0457

Published: 03 May 2022

View article titled, IDO Vaccine Ablates Immune-Suppressive Myeloid Populations and Enhances Antitumor Effects Independent of Tumor Cell IDO Status

Includes: Supplementary data

Journal Articles

Antigen-Specific Antitumor Responses Induced by OX40 Agonist Are Enhanced by the IDO Inhibitor Indoximod

Zuzana Berrong, Mikayel Mkrtichyan, Shamim Ahmad, Mason Webb, Eslam Mohamed, Grigori Okoev, Adelaida Matevosyan, Rajeev Shrimali, Rasha Abu Eid, Scott Hammond, John E. Janik, Samir N. Khleif

Cancer Immunol Res (2018) 6 (2): 201–208.

https://doi.org/10.1158/2326-6066.CIR-17-0223

Published: 31 January 2018

View article titled, Antigen-Specific Antitumor Responses Induced by OX40 Agonist Are Enhanced by the IDO Inhibitor Indoximod

Journal Articles

Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis

Rajeev K. Shrimali, Shamim Ahmad, Vivek Verma, Peng Zeng, Sudha Ananth, Pankaj Gaur, Rachel M. Gittelman, Erik Yusko, Catherine Sanders, Harlan Robins, Scott A. Hammond, John E. Janik, Mikayel Mkrtichyan, Seema Gupta, Samir N. Khleif

Cancer Immunol Res (2017) 5 (9): 755–766.

https://doi.org/10.1158/2326-6066.CIR-17-0292

Published: 31 August 2017

View article titled, Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis

Includes: Supplementary data

Journal Articles

Old-School Chemotherapy in Immunotherapeutic Combination in Cancer, A Low-cost Drug Repurposed

Rasha Abu Eid, Ghazaleh Shoja E. Razavi, Mikayel Mkrtichyan, John Janik, Samir N. Khleif

Cancer Immunol Res (2016) 4 (5): 377–382.

https://doi.org/10.1158/2326-6066.CIR-16-0048

Published: 01 May 2016

View article titled, Old-School Chemotherapy in Immunotherapeutic Combination in Cancer, A Low-cost Drug Repurposed

Journal Articles

Mutant KRAS Conversion of Conventional T Cells into Regulatory T Cells

Stephanie Zdanov, Magis Mandapathil, Rasha Abu Eid, Saudat Adamson-Fadeyi, Willie Wilson, Jiahua Qian, Andrea Carnie, Nadya Tarasova, Mikayel Mkrtichyan, Jay A. Berzofsky, Theresa L. Whiteside, Samir N. Khleif

Cancer Immunol Res (2016) 4 (4): 354–365.

https://doi.org/10.1158/2326-6066.CIR-15-0241

Published: 31 March 2016

View article titled, Mutant KRAS Conversion of Conventional T Cells into Regulatory T Cells

Includes: Supplementary data

Journal Articles

Abstract A047: Safety and clinical activity of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC)

Cancer Immunol Res (2016) 4 (1_Supplement): A047.

https://doi.org/10.1158/2326-6074.CRICIMTEATIAACR15-A047

Published: 03 January 2016

View article titled, Abstract A047: Safety and clinical activity of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC)

Journal Articles

Selective Inhibition of Regulatory T Cells by Targeting the PI3K–Akt Pathway

Rasha Abu-Eid, Raed N. Samara, Laurent Ozbun, Maher Y. Abdalla, Jay A. Berzofsky, Kevin M. Friedman, Mikayel Mkrtichyan, Samir N. Khleif

Cancer Immunol Res (2014) 2 (11): 1080–1089.

https://doi.org/10.1158/2326-6066.CIR-14-0095

Published: 02 November 2014

View article titled, Selective Inhibition of Regulatory T Cells by Targeting the PI3K–Akt Pathway

Journal Articles

Episomal Expression of Truncated Listeriolysin O in LmddA-LLO–E7 Vaccine Enhances Antitumor Efficacy by Preferentially Inducing Expansions of CD4⁺FoxP3⁻ and CD8⁺ T Cells

Zhisong Chen, Laurent Ozbun, Namju Chong, Anu Wallecha, Jay A. Berzofsky, Samir N. Khleif

Cancer Immunol Res (2014) 2 (9): 911–922.

https://doi.org/10.1158/2326-6066.CIR-13-0197

Published: 02 September 2014

View article titled, Episomal Expression of Truncated Listeriolysin O in LmddA-LLO–E7 Vaccine Enhances Antitumor Efficacy by Preferentially Inducing Expansions of CD4+FoxP3− and CD8+ T Cells

Includes: Supplementary data

NARROW

IDO Vaccine Ablates Immune-Suppressive Myeloid Populations and Enhances Antitumor Effects Independent of Tumor Cell IDO Status

Antigen-Specific Antitumor Responses Induced by OX40 Agonist Are Enhanced by the IDO Inhibitor Indoximod

Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis

Old-School Chemotherapy in Immunotherapeutic Combination in Cancer, A Low-cost Drug Repurposed

Mutant KRAS Conversion of Conventional T Cells into Regulatory T Cells

Abstract A047: Safety and clinical activity of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC)

Selective Inhibition of Regulatory T Cells by Targeting the PI3K–Akt Pathway

Episomal Expression of Truncated Listeriolysin O in LmddA-LLO–E7 Vaccine Enhances Antitumor Efficacy by Preferentially Inducing Expansions of CD4⁺FoxP3⁻ and CD8⁺ T Cells

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only